Limits...
A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis.

Wang L, Guo GY, Wang JB, Zhou XM, Yang Q, Han ZY, Li Q, Zhang JW, Cai Y, Ren XL, Zhou X, Chen RR, Shi YQ, Han Y, Fan DM - Sci Rep (2015)

Bottom Line: We found that the basal serum LAMP-2 level was increased in PBC, especially in patients with stage III-IV (p = 0.010) or TBIL > 1 mg/dL (p = 0.014).Baseline serum LAMP-2 was higher in non-responders than that in responders, but the difference was statistically insignificant.However, after UDCA treatment, serum LAMP-2 level decreased prominently in the first 3 months, which was more obvious in responders.

View Article: PubMed Central - PubMed

Affiliation: Division of Hepatology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xian, 710032, Shaanxi Province, China.

ABSTRACT
Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) is variable. We have previously reported that augmented expression of lysosome-associated membrane protein 2 (LAMP-2) was correlated with the severity of PBC. This study aimed to determine whether serum LAMP-2 could serve as a predictor of biochemical response to UDCA. The efficiency of serum LAMP-2 to predict biochemical response was assessed after 1 year of UDCA treatment in PBC patients by a retrospective analysis. We found that the basal serum LAMP-2 level was increased in PBC, especially in patients with stage III-IV (p = 0.010) or TBIL > 1 mg/dL (p = 0.014). Baseline serum LAMP-2 was higher in non-responders than that in responders, but the difference was statistically insignificant. However, after UDCA treatment, serum LAMP-2 level decreased prominently in the first 3 months, which was more obvious in responders. Further studies showed that the 35% decline of LAMP-2 after treatment for 3 months could be stated as an indicator of UDCA response with the sensitivity of 62.9% and specificity of 75.0% by Paris criteria. Meanwhile the specificity and sensitivity were identified as 63.5% and 64.1% by Barcelona criteria. Together, a decline in LAMP-2 might help to predict the response to UDCA.

No MeSH data available.


Related in: MedlinePlus

Clinical significance of LAMP-2 decrease for identifying biochemical response at 3 months of UDCA therapy.Among patients with PBC (n = 102), LAMP-2 decrease had an area under the ROC curve of 0.741 (95%CI: 0.641-0.840) by Paris criteria (a) or 0.717 (95%CI: 0.614-0.820) by Barcelona criteria (b) to identify biochemical response at 3 months of UDCA therapy in patients with PBC.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4403591&req=5

f5: Clinical significance of LAMP-2 decrease for identifying biochemical response at 3 months of UDCA therapy.Among patients with PBC (n = 102), LAMP-2 decrease had an area under the ROC curve of 0.741 (95%CI: 0.641-0.840) by Paris criteria (a) or 0.717 (95%CI: 0.614-0.820) by Barcelona criteria (b) to identify biochemical response at 3 months of UDCA therapy in patients with PBC.

Mentions: When LAMP-2 decline was used to identify biochemical response at 3 months of UDCA therapy among the 102 patients with PBC, the area under the ROC (Receiver Operating Characteristic) curve for LAMP-2 decline was 0.741 (95%CI: 0.641-0.840; Fig. 5a) by Paris criteria, or 0.717 (95%CI: 0.614-0.820; Fig. 5b) by Barcelona criteria. Furthermore, a decrease in LAMP-2 greater than 35% was observed with a predictability of 67% to response by Paris definitions, alongside a sensitivity of 62.9% and a specificity of 75.0%. While defined by Barcelona criteria, the predictability was 64%, alongside a sensitivity of 63.5% and a specificity of 64.1%. These results indicated that the 35% decline of LAMP-2 level after treatment for 3 months could be stated as an indicator of UDCA response.


A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis.

Wang L, Guo GY, Wang JB, Zhou XM, Yang Q, Han ZY, Li Q, Zhang JW, Cai Y, Ren XL, Zhou X, Chen RR, Shi YQ, Han Y, Fan DM - Sci Rep (2015)

Clinical significance of LAMP-2 decrease for identifying biochemical response at 3 months of UDCA therapy.Among patients with PBC (n = 102), LAMP-2 decrease had an area under the ROC curve of 0.741 (95%CI: 0.641-0.840) by Paris criteria (a) or 0.717 (95%CI: 0.614-0.820) by Barcelona criteria (b) to identify biochemical response at 3 months of UDCA therapy in patients with PBC.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4403591&req=5

f5: Clinical significance of LAMP-2 decrease for identifying biochemical response at 3 months of UDCA therapy.Among patients with PBC (n = 102), LAMP-2 decrease had an area under the ROC curve of 0.741 (95%CI: 0.641-0.840) by Paris criteria (a) or 0.717 (95%CI: 0.614-0.820) by Barcelona criteria (b) to identify biochemical response at 3 months of UDCA therapy in patients with PBC.
Mentions: When LAMP-2 decline was used to identify biochemical response at 3 months of UDCA therapy among the 102 patients with PBC, the area under the ROC (Receiver Operating Characteristic) curve for LAMP-2 decline was 0.741 (95%CI: 0.641-0.840; Fig. 5a) by Paris criteria, or 0.717 (95%CI: 0.614-0.820; Fig. 5b) by Barcelona criteria. Furthermore, a decrease in LAMP-2 greater than 35% was observed with a predictability of 67% to response by Paris definitions, alongside a sensitivity of 62.9% and a specificity of 75.0%. While defined by Barcelona criteria, the predictability was 64%, alongside a sensitivity of 63.5% and a specificity of 64.1%. These results indicated that the 35% decline of LAMP-2 level after treatment for 3 months could be stated as an indicator of UDCA response.

Bottom Line: We found that the basal serum LAMP-2 level was increased in PBC, especially in patients with stage III-IV (p = 0.010) or TBIL > 1 mg/dL (p = 0.014).Baseline serum LAMP-2 was higher in non-responders than that in responders, but the difference was statistically insignificant.However, after UDCA treatment, serum LAMP-2 level decreased prominently in the first 3 months, which was more obvious in responders.

View Article: PubMed Central - PubMed

Affiliation: Division of Hepatology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xian, 710032, Shaanxi Province, China.

ABSTRACT
Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) is variable. We have previously reported that augmented expression of lysosome-associated membrane protein 2 (LAMP-2) was correlated with the severity of PBC. This study aimed to determine whether serum LAMP-2 could serve as a predictor of biochemical response to UDCA. The efficiency of serum LAMP-2 to predict biochemical response was assessed after 1 year of UDCA treatment in PBC patients by a retrospective analysis. We found that the basal serum LAMP-2 level was increased in PBC, especially in patients with stage III-IV (p = 0.010) or TBIL > 1 mg/dL (p = 0.014). Baseline serum LAMP-2 was higher in non-responders than that in responders, but the difference was statistically insignificant. However, after UDCA treatment, serum LAMP-2 level decreased prominently in the first 3 months, which was more obvious in responders. Further studies showed that the 35% decline of LAMP-2 after treatment for 3 months could be stated as an indicator of UDCA response with the sensitivity of 62.9% and specificity of 75.0% by Paris criteria. Meanwhile the specificity and sensitivity were identified as 63.5% and 64.1% by Barcelona criteria. Together, a decline in LAMP-2 might help to predict the response to UDCA.

No MeSH data available.


Related in: MedlinePlus